Submissions

Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
  • I, the submitting author, warrant that, where applicable, I have the permission of all co-authors to submit this version of the manuscript according to the journal's criteria for authorship (https://medicaljournalssweden.se/actaoncologica/authorshippolicy) and to be their spokesperson during the review process and beyond. I also approve distribution with the CC license the journal uses, and this too has been approved by co-authors.
  • All authors of the manuscript are qualified to be considered as such, in accordance with the guidelines set forth in the criteria for authorship (https://medicaljournalssweden.se/actaoncologica/authorshippolicy) and all have given their permission to be credited in the submitted manuscript. Anyone who contributed to the work that does not meet the criteria for authorship is listed in the acknowledgments section.
  • The manuscript has not been previously published in the current submitted version, nor is it under consideration by another journal. If the manuscript has been published in an earlier version, this should be clearly indicated; see the journal's editorial guidelines [LINK ]. (Feel free to enter an explanation in the box "Comments to the editor" if relevant).
  • The submitting author has entered their ORCiD identification number in their author data. Any co-authors have been advised to also provide one in accordance with journal policy (https://medicaljournalssweden.se/actaoncologica/policyforORCiD).
  • All material presented in the manuscript where copyright is held by third parties has been properly produced and necessary permissions have been obtained by the submitting author.
  • The text follows the stylistic and bibliographic requirements specified in the author instructions (https://medicaljournalssweden.se/actaoncologica/authorguidelines)
  • All individuals or groups of individuals who can be identified in a study, or their guardians, have signed informed consent documents, thereby giving their consent for the submitted manuscript to be published under a CC license.
  • Where applicable, the research has been reviewed by an appropriate ethics committee and the name of the committee and approval reference number are included in the submitted manuscript.
  • Upon acceptance of the manuscript, the author(s) agrees to pay the publication fee as per the journal’s publication fee policy (Article Processing Charge, APC) (https://medicaljournalssweden.se/actaoncologica/APC)
  • Illustrations should be of high quality (1200 dpi for line art, 600 dpi for grayscale and 300 dpi for colour, at the correct size) and should be submitted as separate files in the formats EPS, PS, JPEG, GIF or tiff. The figure number should be indicated in the file name. Figure legends should be provided on the last page of the main text. Letters and numerals should be large enough to allow the reduction of illustrations to one column. Illustrations should preferably be provided in colour (CMYK colours). The use of symbols should be consistent between figures.

Author Guidelines

Submissions to Acta Oncologica are done on the basis that:

  • The work has not previously been published in any language or is under consideration in another journal
  • Previous or parallel publication of part of the work is specified in the manuscript and in the cover letter
  • All authors have read and approved the manuscript
  • Relevant permission for the reproduction of images has been obtained
  • Original data related to the manuscript should be retained and retrievable for a minimum of 10 years from the online publication date
  • Author(s) agree to all terms in Acta Oncologica’s submission checklist upon submission

The journal welcomes articles in the following areas:

Peer Review: 
Acta Oncologica conducts single-blinded peer review and requires evaluation by two independent experts who are asked to highlight the manuscript's general and specific merits and shortcomings. The process is expected to take 4-8 weeks but may vary. Most manuscripts undergo one-three rounds of revision prior to acceptance.
For more information please see: Editorial policy and review process

Preparing your manuscript

All authors submitting contributions to Acta Oncologica should meet the authorship requirements and conform to the requirements of the International Committee of Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts Submitted to Biomedical Journals.

Please supply the manuscript typed with double spacing throughout.

The text should be divided into the sections: Introduction, Patients/Materials and Methods, Results, and Discussion. For original articles and review articles a structured abstract should be provided.

Please use British or US spelling style consistently throughout your manuscript. Manuscripts are expected to have a high standard of English and should typically have undergone professional English review.

Acta Oncologica endorses the use of an appropriate reporting guideline when writing manuscripts. Please refer to the EQUATOR network (www.equator-network.org), which also gives general information on how to choose the correct guidelines. At a minimum, your article should report the content addressed by each item and provide the relevant checklist as supplementary information. Meeting these reporting requirements will improve the manuscript and facilitate/enhance the peer review process.

Abbreviations, which are not generally accepted, should be spelt out when first used in the text.

Title page
The title should be informative, reflecting the content of the study and should preferably be expressive.

Authors should be listed with first name, middle initial(s), and last name with department affiliations. An e-mail address to the corresponding author should be provided. Please also add ORCID identifiers. Shared authorship of a maximum of two authors is allowed. 

Word limits
Please include a word count of your manuscript on the title page, excluding word count associated with tables, references, figures, and all information held on the title page.

Original manuscripts and reviews have a word limit of 3500 words and up to 7 tables/figures.

Short reports have a word limit of 2000 words and up to 3 tables/figures and require a structured abstract. Study protocols are published as short reports.

Letters and Commentaries have a word limit of 1000 words and may contain one table/figure, if relevant for the content. 

Editorials have a word limit of 2000 words and may contain 1 table/figure, if relevant for the content. 

Additional materials may be provided as supplementary materials without any cost. 

Abstract
Abstracts should be provided for original articles, short reports and review articles (but should not be provided for letters, commentaries and editorials). The abstract should not exceed 250 words and should be structured into; Background and purpose, Patients/material and methods, Results and Interpretation.

The provision of a graphical abstract is optional and encouraged. The image should have a maximum width of 525 pixels and should be provided as a separate file in the formats .jpg, .png, or .gif.

Keywords
Please provide 4-7 keywords that should be selected from a search engine to optimize relevance and specificity. Avoid duplication of words already in the article’s title.

Introduction
The introduction should focus on the state of knowledge at the beginning of the study and should define the research gap. The aims and main hypothesis of the study should be stated clearly.

Patients/material and methods
Study type should be defined with reference to the relevant EQUATOR guideline. The manuscript should be formatted accordingly and as a minimum, the relevant EQUATOR guideline checklist should be provided as supplementary information. Statistics should provide relevant information on software and analytical procedures and should whenever relevant refer to a data management plan. Please use SI units (non-italicized) when relevant.

Results
Results should be structured into a logical flow. Text and figures/tables should be complementary and not overlapping. Measures of variability should be provided and a limited number of decimals should be provided.

Discussion
The discussion should critically discuss the findings, including data quality, and analytical limitations and should put the findings into perspective with reference to relevant literature. A section on strengths and limitations should be provided and the final section should present a study conclusion.

Tables
Tables should present new information rather than duplicating what is in the text. Readers should be able to interpret the table without reference to the text. Tables should be provided double-spaced on a separate page as editable files. Do not submit tables as photographs. Supply a brief title for each table. Each column should have a short heading. Explanatory matters should be placed in notes under the table.

Short reports have a word limit of 2000 words and up to 3 tables/figures. Study protocols are published as short reports.

Letters and Commentaries have a word limit of 1000 words.

Editorials have a word limit of 2000 words and may contain up to 3 tables/figures.

Illustrations
Illustrations should be of high quality (1200 dpi for line art, 600 dpi for grayscale and 300 dpi for colour, at the correct size) and should be submitted as separate files in the formats EPS, PS, JPEG, GIF or tiff. The figure number should be indicated in the file name. Figure legends should be provided on the last page of the main text. Letters and numerals should be large enough to allow the reduction of illustrations to one column. Illustrations should preferably be provided in colour (CMYK colours). The use of symbols should be consistent between figures.

Author contributions
Describe in short what each author did (initials).

Acknowledgements
Relevant funding should be reported and technical support may be acknowledged. Please include “This work was supported by the [Funding Agency] under Grant [number xxxx].”
For multiple agency grants: This work was supported by the [Funding Agency 1];

References
The number of references should be limited to 25-35 (except for meta-analyses and review articles). References should be consecutively numbered and referred to in the text by their number within brackets. When available, DOI numbers should be added to the references.

For further details regarding references, see https://www.nlm.nih.gov/bsd/uniform_requirements.html#journals.

If there are six or fewer authors, state all in the reference list. If there are more than six, state the first six and use et al. for additional authors.

Clausen CT, Hasle H, Holmqvist AS, Madanat-Harjuoja L, Tryggvadottir L, Wesenberg F et al. Hyperthyroidism as a late effect in childhood cancer survivors - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study. Acta Oncol. 2018;26:1-5

Johansen C, Dalton SO. Survivorship in new harbors. Acta Oncol. 2017;56:119–122.

Disclosure statements
Any financial or non-financial interest that has arisen from the direct applications of your research should be reported. If there are no relevant competing interests to declare please state “The authors report there are no competing interests to declare.” 

Data availability statement
Authors are required to provide a data availability statement that provides information on where data used for the paper can be found and how it can be accessed. If data cannot be made open, authors should state why in the data availability statement. If the data is open, please deposit the data in a recognized data repository prior to or at the time of submission and include the DOI, pre-reserved DOI, or other persistent identifier for the data set.

Ethics declarations & trial registry information
Please ensure that all research reported in submitted papers has been conducted in an ethical and responsible manner, and is in full compliance with all relevant codes of experimentation and legislation. All original research papers involving humans, animals, plants, biological material, protected or non-public datasets, collections or sites, providing the approval number from the appropriate ethics committee or Institutional Review Board and that where relevant, informed consent has been obtained. For clinical studies, please provide trial registry identifiers/approval numbers in ClinicalTrials.gov.

Supplemental material
Supplemental material can be data, images, video or other relevant information that supports and is pertinent to the paper. Please submit supplementary materials as a separate file.

Copyright Notice

Authors of current content published in Acta Oncologica retain copyright to their works. Articles are published under the terms of a Creative Commons license CC-BY 4.0, which permits use, downloading, distribution, linking to, and reproduction in any medium, provided the original work is properly cited. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication. 

All commercial requests to re-use an article published in whole or in part under the previously used license (CC-NC-BY) will be handled by the Acta Oncologica Foundations through contact to editor@actaoncologica.se. Any permission fees will be retained by this organization. For the purposes of these terms, “commercial use” means use in any manner that is primarily intended for or directed toward commercial advantage or monetary compensation, including but not limited to provision or distribution (including by way of hyperlink) of the article (including any abstract, figures or tables) in any format. For further information on the commercial use of published papers please contact us.

Authors are encouraged to deposit the final published version of their article for self-archiving (author's personal website) and/or archiving in an institutional archive immediately after publication.

When publishing articles in Acta Oncologica, the author(s) grant first publication rights to Medical Journals Sweden. In consideration of the publication of the article, the authors grant Acta Oncologica the licence to 1) publish, reproduce, distribute, display and store the article worldwide in all forms, formats and media now known or as developed in the future, including print, electronic and digital forms, and 2) to translate the article into other languages, create adaptations, summaries or extracts of the article. Please note that authors are themselves responsible for obtaining permission for reproducing copyrighted material from other sources.

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party. The data collected from registered and non-registered users of this journal falls within the scope of the standard functioning of peer-reviewed journals. Hence it:

  • includes information that makes communication possible for the editorial process;
  • is used to inform readers about the authorship and editing of content;
  • enables collecting aggregated data on readership behaviour.